RT @net_connectinfo: Clinical and patient-reported outcomes of #TE in carcinoid syndrome diarrhea #CSD in combination with #SSAs. After 6…
Clinical and patient-reported outcomes of #TE in carcinoid syndrome diarrhea #CSD in combination with #SSAs. After 6 months: 🔴76% satisfied with CS symptom control 🔴78% satisfied with CSD control New study by @AmanChauhanMD et al: 👉https://t.co/YW6UC
Patients receiving telotristat ethyl in the RELAX study | CMAR #carcinoidsyndrome #neuroendocrine #research @DovePress https://t.co/piCvR48489
RT @AmanChauhanMD: Building up excitement for #NANETS22 Checkout our work: Longitudinal observational study evaluating QoL parameters wit…
RT @DanengLi: Wonderful to have done this with @AmanChauhanMD and team. Real World Data showing benefit of Telotristat Ethyl on #QoL in NET…
Wonderful to have done this with @AmanChauhanMD and team. Real World Data showing benefit of Telotristat Ethyl on #QoL in NET pts @LACNETS @CarcinoidNETs @CureNETs @NANETS1 @UKMarkey @COHMedOnc @cityofhope
RT @RonnyAllan1: Patients receiving telotristat ethyl in the RELAX study | CMAR #NeuroendocrineCancer https://t.co/PmLdik66LB https://t.co/…
Building up excitement for #NANETS22 Checkout our work: Longitudinal observational study evaluating QoL parameters with Telotristat Ethyl. Wonderfully lead by @DanengLi #QoL matters #RealWorldData #CarcinoidSyndrome 🦓 @UKMarkey @COHMedOnc @NANETS1 http
Patients receiving telotristat ethyl in the RELAX study | CMAR #NeuroendocrineCancer https://t.co/PmLdik66LB https://t.co/kGiUoZ3XPD